Cargando…
Novel Bifunctional Affibody Molecules with Specific Binding to Both EBV LMP1 and LMP2 for Targeted Therapy of Nasopharyngeal Carcinoma
Antibodies are considered highly specific therapeutic agents in cancer medicines, and numerous formats have been developed. Among them, bispecific antibodies (BsAbs) have gained a lot of attention as a next-generation strategy for cancer therapy. However, poor tumor penetration is a major challenge...
Autores principales: | Kamara, Saidu, Guo, Yanru, Wen, He, Liu, Ying, Liu, Lei, Zheng, Maolin, Zhang, Jing, Zhou, Luqi, Chen, Jun, Zhu, Shanli, Zhang, Lifang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299379/ https://www.ncbi.nlm.nih.gov/pubmed/37373272 http://dx.doi.org/10.3390/ijms241210126 |
Ejemplares similares
-
EBV LMP1-C terminal binding affibody molecule downregulates MEK/ERK/p90RSK pathway and inhibits the proliferation of nasopharyngeal carcinoma cells in mouse tumor xenograft models
por: Guo, Yanru, et al.
Publicado: (2023) -
Novel EBV LMP-2-affibody and affitoxin in molecular imaging and targeted therapy of nasopharyngeal carcinoma
por: Zhu, Shanli, et al.
Publicado: (2020) -
Generation of novel affibody molecules targeting the EBV LMP2A N-terminal domain with inhibiting effects on the proliferation of nasopharyngeal carcinoma cells
por: Zhu, Jinshun, et al.
Publicado: (2020) -
Correction: Generation of novel affibody molecules targeting the EBV LMP2A N-terminal domain with inhibiting effects on the proliferation of nasopharyngeal carcinoma cells
por: Zhu, Jinshun, et al.
Publicado: (2020) -
A Therapeutic Approach to Nasopharyngeal Carcinomas by DNAzymes Targeting EBV LMP-1 Gene
por: Yang, Lifang, et al.
Publicado: (2010)